AVAILABLE TREATMENTS
• Onpattro
• Amvuttra
TREATMENT DURATION
~ 80 minutes
FREQUENCY OF TREATMENT
Every 3 Weeks
HOW TO BOOK A TREATMENT
CONDITION AND TREATMENT OVERVIEW
hATTR Amyloidosis
It can be overwhelming and terrifying to receive a diagnosis for a rare, progressive disease. The unknowns just pile up, leaving you wondering what your future might hold. If you are one of 50,000 people worldwide living with Hereditary transthyretin-mediated (hATTR) amyloidosis (hATTR Amyloidosis), you are not alone, Infusion for Health is here for you.
If your doctor has prescribed infusion therapy for the management of symptoms for hATTR Amyloidosis, then Infusion for Health can help. Call our office today to find out more.
AVAILABLE TREATMENTS
• Onpattro
• Amvuttra
TREATMENT DURATION
~ 80 minutes
FREQUENCY OF TREATMENT
Every 3 Weeks
HOW TO BOOK A TREATMENT
What is hATTR Amyloidosis?
An often-misdiagnosed disease, hATTR amyloidosis is a rare, inherited, rapidly progressing condition caused by a mutation in the transthyretin (TRR) gene. This mutation causes the TRR protein that is made in the liver to be created with misfolds, leading to an accumulation of amyloid deposits (proteins and peptides) on multiple tissues including the heart, nerves, and digestive system. Ultimately it can lead to debilitating and life-threatening symptoms such as:
- Pain & Weakness of the limbs
- Swollen legs
- Heart-related issues
- Kidney dysfunction
- Excessive sweating, shortness of breath & dizziness
- Gastric symptoms-nausea, vomiting, diarrhea & constipation
- Urinary tract infections
- Carpal tunnel syndrome
- Unintentional weight loss
- Sexual dysfunction
- Glaucoma, blurry vision, floaters in the eye
- Dementia
hATTR amyloidosis is a hereditary autosomal dominant disease, meaning you only need to inherit one copy of the mutated TTR gene to present the disease. As a multisystemic disease, presentation of symptoms and the severity will vary from person to person. The onset of hATTR amyloidosis can also vary, usually showing up in adults in their mid-20’s to mid-60’s.
